Literature DB >> 33990857

Fatty acids promote the expansion of NK-92 cells in vitro by improving energy metabolism.

Zhepei Xie1, Yan Fu1, Wen-Song Tan1, Haibo Cai2.   

Abstract

Natural killer-92 cells (NK-92 cells) need to be efficiently expanded by serum-free culture in vitro to meet clinical requirements. Fatty acids mainly provide substrates for energy production, which is of crucial importance to meet the energy demands of highly proliferating cells. This study optimized the medium (EM) for NK-92 cells by designing an experiment to expand cells efficiently. EM, an in-house designed chemically defined serum-free medium, was used as the basal medium. Fatty acids as additive ingredients were screened and optimized by the experimental design method. Three additives, arachidonic acid, myristic acid and palmitoleic acid, were screened; therefore, the optimized medium was named EM-FA. The total cell expansion of NK-92 cells in EM-FA was 72.61±11.95-fold on day 8, which was significantly higher than the 28.55±8.67-fold expansion in EM. To explore the mechanism by which fatty acids promote NK-92 cell expansion, the cell growth kinetics and metabolic characteristics in EM-FA were analyzed. The results showed that NK-92 cells in EM-FA were rapidly expanded while maintaining their cell phenotype and cytotoxicity and enhancing the oxygen consumption rate and mitochondrial function. Fatty acids promoted ATP production to elevate the energy flux for better cell expansion. This study developed an expansion strategy of NK-92 cells in vitro to facilitate their clinical application. KEY POINTS: • Arachidonic acid, myristic acid and palmitoleic acid in serum-free medium were optimized by experimental design to enable the rapid expansion of NK-92 cells in vitro. • Fatty acids upregulated oxidative phosphorylation levels and improved the energy metabolism of NK-92 cells.

Entities:  

Keywords:  Fatty acid; Medium; Metabolism; NK-92 cell; Proliferation

Year:  2021        PMID: 33990857     DOI: 10.1007/s00253-021-11313-y

Source DB:  PubMed          Journal:  Appl Microbiol Biotechnol        ISSN: 0175-7598            Impact factor:   4.813


  20 in total

1.  Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer.

Authors:  Bihui Cao; Manting Liu; Lu Wang; Baoxia Liang; Yunfei Feng; Xiaopei Chen; Yuanyuan Shi; Jinling Zhang; Xiaodie Ye; Yu Tian; Cheng Zhi; Junping Li; Hui Lian; Qingde Wu; Zhenfeng Zhang
Journal:  Biochem Biophys Res Commun       Date:  2020-01-22       Impact factor: 3.575

2.  Early effector maturation of naïve human CD8+ T cells requires mitochondrial biogenesis.

Authors:  Marco Fischer; Glenn R Bantug; Sarah Dimeloe; Patrick M Gubser; Anne-Valérie Burgener; Jasmin Grählert; Maria L Balmer; Leyla Develioglu; Rebekah Steiner; Gunhild Unterstab; Ursula Sauder; Gideon Hoenger; Christoph Hess
Journal:  Eur J Immunol       Date:  2018-08-07       Impact factor: 5.532

3.  Mammalian lipid droplets are innate immune hubs integrating cell metabolism and host defense.

Authors:  Marta Bosch; Miguel Sánchez-Álvarez; Alba Fajardo; Ronan Kapetanovic; Bernhard Steiner; Filipe Dutra; Luciana Moreira; Juan Antonio López; Rocío Campo; Montserrat Marí; Frederic Morales-Paytuví; Olivia Tort; Albert Gubern; Rachel M Templin; James E B Curson; Nick Martel; Cristina Català; Francisco Lozano; Francesc Tebar; Carlos Enrich; Jesús Vázquez; Miguel A Del Pozo; Matthew J Sweet; Patricia T Bozza; Steven P Gross; Robert G Parton; Albert Pol
Journal:  Science       Date:  2020-10-16       Impact factor: 47.728

Review 4.  Mitochondrial ROS regulation of proliferating cells.

Authors:  Lauren Diebold; Navdeep S Chandel
Journal:  Free Radic Biol Med       Date:  2016-05-03       Impact factor: 7.376

5.  Genome-wide analyses and functional profiling of human NK cell lines.

Authors:  Justin T Gunesch; Laura S Angelo; Sanjana Mahapatra; Raquel P Deering; Johanna E Kowalko; Patrick Sleiman; John W Tobias; Linda Monaco-Shawver; Jordan S Orange; Emily M Mace
Journal:  Mol Immunol       Date:  2018-07-24       Impact factor: 4.407

6.  EBV reduces autophagy, intracellular ROS and mitochondria to impair monocyte survival and differentiation.

Authors:  M S Gilardini Montani; R Santarelli; M Granato; R Gonnella; M R Torrisi; A Faggioni; M Cirone
Journal:  Autophagy       Date:  2018-10-23       Impact factor: 16.016

7.  Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia.

Authors:  Michael Boyiadzis; Mounzer Agha; Robert L Redner; Alison Sehgal; Annie Im; Jing-Zhou Hou; Rafic Farah; Kathleen A Dorritie; Anastasios Raptis; Seah H Lim; Hong Wang; Natalia Lapteva; Zhuyong Mei; Lisa H Butterfield; Cliona M Rooney; Theresa L Whiteside
Journal:  Cytotherapy       Date:  2017-08-30       Impact factor: 5.414

Review 8.  Natural Killer Cells for Immunotherapy - Advantages of the NK-92 Cell Line over Blood NK Cells.

Authors:  Hans Klingemann; Laurent Boissel; Frances Toneguzzo
Journal:  Front Immunol       Date:  2016-03-14       Impact factor: 7.561

9.  Mitochondria-derived ROS activate AMP-activated protein kinase (AMPK) indirectly.

Authors:  Elizabeth C Hinchy; Anja V Gruszczyk; Robin Willows; Naveenan Navaratnam; Andrew R Hall; Georgina Bates; Thomas P Bright; Thomas Krieg; David Carling; Michael P Murphy
Journal:  J Biol Chem       Date:  2018-09-19       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.